Vanflyta Now Available for FLT3-ITD Positive Acute Myeloid Leukemia
Vanflyta (quizartinib) is now available for the treatment of newly diagnosed FLT3-ITD positive acute myeloid leukemia.
Source: empr.com
Page 45 - Risk Evaluation News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Risk Evaluation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Risk Evaluation Today - Breaking & Trending Today
Ammon Bundy, co-defendants to pay $52.5M in Idaho system harassment lawsuit
Jury orders Ammon Bundy, Diego Rodriguez, People's Rights Network, Freedom Man Press, and the Bundy campaign for governor to pay $52.5 million in damages for al
Source: beckershospitalreview.com
Vanflyta Approved for Newly Diagnosed FLT3-ITD AML
The FDA has approved Vanflyta (quizartinib) to treat adults with newly diagnosed FLT3-ITD acute myeloid leukemia.
Source: cancertherapyadvisor.com
FDA Approves Quizartinib for Newly Diagnosed AML
Cardiac risks mean the targeted tyrosine kinase inhibitor is available only through a REMS program.
Source: medscape.com
Trends in the Use of Mifepristone for Medical Management of Early Pregnancy Loss From 2016 to 2020
This study assesses the use of mifepristone plus misoprostol for miscarriage management among commercially insured adults in the US.
Source: jamanetwork.com